We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




HPV Testing Offers Women Longer Protection than Smear Testing

By Labmedica staff writers
Posted on 21 May 2008
Testing for human papillomavirus (HPV) can be twice as effective at protecting women from developing cervical abnormalities as smear testing.

Nearly 3000 women aged 35+ were recruited into a study between April 1994 and September 1997. More...
They were asked to participate in the study in which HPV testing would be performed in addition to cytology (smear test) whilst attending their general practitioner (GP) practice (40 practices were involved in the trial) for a routine cervical smear.

All women tested were followed up passively using data from the national computerized system that records all smears and their results--the Open-Exeter system. Women with a smear history indicating the need for colposcopy--a more thorough examination of the cervix--were investigated further to determine whether the colposcopy and biopsy were performed, and what the resultant outcome was. Passive follow-up was complete for all women by early 2005.

Results showed that the risk of developing cervical abnormalities at one, five, and nine years after a normal smear test was 0.33%, 0.83%, and 2.20% respectively, with those odds significantly reduced after a negative HPV test--0.19%, 0.42%, and 1.88%, respectively.

The study was led by Prof. Jack Cuzick of Barts and The London School of Medicine and Dentistry (London, UK) and the results were published on May 15, 2008, in the International Journal of Cancer.

Prof. Cuzick said that HPV testing "offers women excellent protection from cervical abnormalities for at least six years after a negative test, compared to protection from a normal smear test which begins to wane after about three years. This suggests that the screening interval can be safely extended to at least six years with HPV testing. These data provide more support for replacing screening based on abnormal cells, with a more sensitive test based on screening for the human papillomavirus.”


Related Links:
Barts and The London School of Medicine and Dentistry

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Biochemical Analyzer
iBC 900
New
Automated PCR Setup
ESTREAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Pathology

view channel
Image: Micrograph showing the distribution of misfolded proteins in myeloma cells (Photo courtesy of Helmholtz Munich)

Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels

Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. Traditional methods for evaluating myeloma... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.